CureDuchenne, a global leader in funding and advancing research for Duchenne muscular dystrophy, today announced a second investment into Tevard Biosciences to support the advancement of the company's ...
Georgian Health Minister Mikheil Sarjveladze said decisions regarding medications for the treatment of Duchenne muscular ...
Georgian Prime Minister Irakli Kobakhidze said that decisions regarding the financing of medication for children with ...
Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle and pulmonary function ...
6d
Regenxbio Meets Primary Endpoint in Duchenne Muscular Dystrophy Study, Swings to 1Q Loss -- Update
Regenxbio met its primary endpoint in a Phase 3 study of its Duchenne muscular dystrophy treatment, but it swung to a first-quarter loss as revenue plunged. Shares fell 20% to $8.06 in premarket ...
Muhammad Umer Khalid was denied bail despite medical evidence indicating that his condition had deteriorated partly due to ...
Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a ...
Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated ...
Strong Buy on WVE-N531 and WVE-006 catalysts, Phase data, and cash runway into 2028. Click for this WVE stock update.
As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies ...
About one in every 3,500-5,000 boys worldwide is born with Duchenne Muscular Dystrophy, or DMD, a rare genetic condition that ...
Regenxbio announces positive results from pivotal phase III AFFINITY DUCHENNE study of RGX-202 to treat Duchenne muscular dystrophy: Rockville, Maryland Friday, May 15, 2026, 14:0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results